S100A8 and COVID-19: Although there is no application of alarmin blockade in COVID-19 and comorbidities, previous studies have suggested the therapeutic potential of neutralizing antibodies against S100A8/A9, HMGB1, or histones for the inhibition of pulmonary fibrosis and sepsis-associated ALI/ARDS [70,71,72,73].